Dr. David Samadi is a distinguished medical practitioner and Chief of Robotic Surgery at Lenox Hill Hospital which is based in New York City. Dr. Samadi also serves as Chairman of Urology in the same hospital. He is especially well versed in diagnosing and in turn treating urologic infections and bladder cancer. Dr. Samadi has also successfully diagnosed and treated a number of prostate cancer and kidney cancer patients from all around the world. He is particularly credited with having conducted several minimally invasive procedures successfully on patients suffering from prostate cancer.
Dr. David Samadi graduated from Stony Brook University with a degree in biochemistry and later went in for the Doctor of Medicine from the same university’s school of medicine. With this foundation, Dr. Samadi went for further training at the Albert Einstein College and Montefiore Medical center where he got more postgraduate training while at the same time gaining much-needed experience from the best in the industry. Given Dr. Samadi’s keen interest in matters urology, he went to Memorial Sloan Kettering Cancer Center where he attended and participated in a fellowship in proctology. In 2001, Dr. Samadi flew to Creteil, France for another fellowship only that this time it was focused on robotic radical prostatectomy. The fellowship was hosted by the Henri Mondor Hospital.
Dr. David Samadi has had a stellar professional career of over 20 years working for various organizations of repute at holding several significant positions. This has seen him travel all around the world performing operations while also helping impart his unique skills to budding medical practitioners. In the year 2007, Dr. Samadi rose to the position of Vice Chair of the Department of Urology at Mount Sinai School of Medicine before moving to Lenox Hill Hospital. Dr. Samadi strongly believes that young people are better placed at furthering the quest for the eradication of all types of cancers from the face of the world and this informed his decision to work as a professor of Urology at Hofstra University’s LIJ School of Medicine.
Dr. David Samadi’s talents are not just limited to matters medicine and urology, this was clearly demonstrated when he served as a host for a TV show on the Fox News Channel for 5 years. The show was known as “Sunday Housecall” and was largely associated with giving medical advice to viewers on different aspects of health.
Read More: www.sharecare.com/doctor/dr-david-samadi-3
Mikhail Blagosklonny, a leading researcher focuses on anti-aging and oncology, explained the healing effects of Rapamycin. It should be noted that the drug that was isolated from Sirolimus bacterium in 1972 was initially used as an anti-fungal medicine. Later, researchers identified the antiproliferative and immunosuppressive properties. However, the studies of Blagosklonny revealed many characteristics of the drug and later helped the physicians to use it for various treatment purposes. He says that immunosuppressant property of the drug makes it an ideal choice for the medication that can be applied to patients who have gone for organ transplantation. Rapamycin can avoid the risk of the organ being rejected by the human body. It also offers a lower level of toxic condition to kidneys compared to other drugs.A rare disease condition of kidney failure, low platelet count, and anemia, hemolytic-uremic syndrome, can be treated using the drug. It is observed that such patients who go for a kidney transplant have a high risk of disease being imparted on the new kidney. Rapamycin gives effective results in such cases by offering lower toxicity levels to the organs.
A sporadic lung disease, Lymphangioleiomyomatosis, that affects women during their pregnancy stage can get the help of the drug as Rapamycin is the primary drug accepted by the board for treatment. While coming to the treatment of cancer, the antiproliferative properties of the medicine ensure an increased immune response in the human body against the cancer cells. It also creates regression against cancer and acts as a preventive medicine.Rapamycin can also efficiently used to treat Tuberous Sclerosis Complex, a congenital disorder that causes benign tumor growth in principal organs of the human body including the brain, kidney, heart, and more. The drug can give excellent results in both youngsters and adults. Blagosklonny says that Rapamycin also alleviates the effects of Facial angiofibromas that are due to TSC. He did extensive research on the anti-age properties of Rapamycin and confirmed that if administered in proper doses, the drug has the capacity to reverse the aging. Interestingly, Blagosklonny conducted the tests on mice and showed that it creates an immunological rejuvenation.
Blagosklonny is also a philanthropist and a well-known professor. He dreams to develop treatment options for cancer that can ensure effective cure while offering affordability to every section of people, regardless of their economic conditions. Blagosklonny also researches on the increased risk of cancer with respect age as he researches in both aging and cancer. Researchers, doctoral students, and physicians around the world follow his researchers and get in touch with him for guidance and assistance. Blagosklonny is also an inspiration to his colleagues and students across the globe.Mikhail Blagosklonny has another ambition of introducing a cancer treatment process that ensures effective remedy to the disease and at the same time, providing a quicker recovery. He is working on a treatment process that can destroy cancer cells efficiently without causing any damage to the healthy cells. Blagosklonny thinks that he should achieve maximum progress in his missions so that other researchers can pick from there and make his dream a reality.